<DOC>
	<DOCNO>NCT02908724</DOCNO>
	<brief_summary>The purpose study assess progression cardiac involvement adult patient Fabry Disease ( FD ) , unique Danish Fabry cohort compare FD patient receive primary therapy vs. . The hypothesis , able see significant positive difference cardiac involvement FD patient receive FD specific therapy vs. .</brief_summary>
	<brief_title>Cardiac Involvement Adult Patients With Fabry Disease ; Relation Enzyme Replacement Therapy</brief_title>
	<detailed_description>Enzyme replacement therapy concomitant treatment : FD specific treatment ( ERT , enzyme replacement therapy ) available since 2001 patient treat either agalsidase alpha ( Replagal® ) agalsidase beta ( Fabrazyme® ) every week recommend dos , 0.2 mg/kg 1.0 mg/kg , respectively . Concomitant treatment cardiovascular medication include angiotensin-converting-enzyme-inhibitor , angiotensin-II-receptor-blocker , acetylsalicylic acid , beta-blocker , calcium-channel-blocker , diuretic statin , register patient . Statistical analysis : Primarily , compare progression cardiac involvement baseline follow-up , accord ERT include subgroup analysis accord gender . Secondarily , subgroup analysis ERT group perform separate patient with- without cardiac disease baseline , indicate presence myocardial hypertrophy transthoracic echocardiography ( septal thickness LV posterior wall thickness &gt; 0.9 cm female &gt; 1.0 male ) , increase cardiac mass ( Left ventricular mass index ( LVMi ) &gt; 95 g/m2 female &gt; 115g/m2 male ) systolic dysfunction ( ejection fraction &lt; 55 % ) accordance guideline American Society Echocardiography European Association Echocardiography ( Lang et al. , 2005 ) . In analysis ERT patient ' baseline define last available examination prior ERT start follow-up last available examination ERT . Inclusion non-ERT group require patient receive ERT study end . Intra-group comparison progression baseline follow-up make McNemar test ( categorical variable ) Wilcoxon Signed Rank Test ( continuous variable ) . Thirdly , comparison treatment group , linear mixed model apply available data continuous variable regard Sokolow-Lyon voltage- , Cornell product ECG criterion LVMi violation assumption linear mixed model test find initial analysis . The modelling allow individual difference general level ( track ) well individual difference progression time , control gender , age baseline , treatment duration current ERT status . Comparisons major organ involvement baseline , gene mutation alfa-galactosidase A activity treatment group , perform Chi-squared Mann-Whitney U test , respectively . Data categorical variable present frequency ( percentage ) , continuous variable present median [ range ] estimate ( ±standard error ) . Data analyse use SPSS ( version 19.0 ) . All test two-sided p-value &lt; 0.05 consider statistically significant .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Genetically verify Fabry disease Age baseline &gt; 18 year Baseline cardiac examination perform Switch FD specific treatment ( Fabrazyme Replagal ) FD specific treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Familial cardiomyopathy</keyword>
	<keyword>Hypertrophic cardiomyopathy</keyword>
	<keyword>Left ventricular hypertrophy</keyword>
</DOC>